19:51 , Nov 2, 2018 |  BC Week In Review  |  Company News

Strongbridge hands off Macrilen to Novo for sizable return

Less than a year after acquiring U.S. and Canadian rights to Macrilen macimorelin acetate, Strongbridge Biopharma plc (NASDAQ:SBBP) handed those rights off to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), netting a 6x return. FDA approved...
20:56 , Oct 31, 2018 |  BC Extra  |  Company News

Strongbridge hands off Macrilen to Novo for sizable return

Less than a year after acquiring U.S. and Canadian rights to Macrilen macimorelin acetate, Strongbridge Biopharma plc (NASDAQ:SBBP) handed those rights off to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), netting a 6x return. FDA approved...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer...
20:29 , Jul 6, 2018 |  BC Extra  |  Company News

Management tracks: Goldman Sachs, Acceleron

One of China's top healthcare analysts, Richard Yeh, said he is departing Goldman Sachs, where he was in global investment research for Asia Pacific. Several Asia-focused bankers and analysts, including Citigroup's Billy Cho, Bank of...
16:20 , May 23, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice treated prenatally with AMH could be used to screen therapies to treat polycystic ovary syndrome, a partially heritable disease. In blood samples from 66 pregnant patients with PCOS, AMH levels were...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
15:01 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA approves Aeterna's Macrilen

FDA approved a resubmitted NDA for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna plans to launch the oral ghrelin-mimetic growth hormone...
20:17 , Dec 21, 2017 |  BC Extra  |  Company News

Aeterna jumps on Macrilen approval

Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) shares climbed Thursday after FDA approved a resubmitted NDA for Macrilen macimorelin acetate for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna added C$0.91 (35%) to C$3.48 in Toronto,...
23:41 , Dec 12, 2017 |  BC Extra  |  Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...